王栋栋

个人简历

王栋栋，临床药学博士，副教授/执业药师，硕士生导师，江苏省“双创博士”，中国药理学会定量药理学专业委员会委员、中国中医药信息学会中医临床药学分会常务理事，2021年毕业于复旦大学（与美国密歇根大学联合培养，国家公派留学）。研究方向为模型引导的临床精准用药、儿科临床药理学与毒理学、定量药理学教育教学研究。以（共）第一/通讯作者在Biomed Pharmacother、Front Pharmacol、Eur J Pharm Sci、Front Nutr、Expert Rev Clin Pharmacol、J Diabetes Res、J Clin Pharm Ther等发表SCI论文40余篇、定量药理学教学论文5篇；担任Front Pharmacol（JCR: Q1）客座副主编，Model-informed drug development and precision dosing in clinical pharmacology practice研究专题客座主编；Current Psychopharmacology编委；International Journal of Pediatrics and Child Health编委；《药物流行病学杂志》特邀审稿人；同时为8本SCI期刊审稿人；主持国家自然科学基金青年科学基金项目、省教育科学“十四五”专项课题等6项；在亚洲临床药学会议（新加坡）、定量药理学与新药评价国际会议、中华医学会临床药学分会、中华医学会全国儿科学术大会、中华医学会肾脏病学分会、全国儿科药学学术年会、全国治疗药物监测学术年会、中国药理学会临床药理学专业委员会青年创新论坛上大会发言、交流及获奖20余次，并在中华医学会临床药学分会2023年全国学术会议上入围高质量论文；指导临床药学专业学生申请创新课题3项、指导学生在第十五届全国大学生药苑论坛中获创新成果一等奖、优秀论文奖；指导学生在长三角高校本科生临床药学技能邀请赛获二等奖。

承担课题（科研课题4项/教学课题2项）

1. 国家自然科学基金青年科学基金项目，82104296，CXCR2通过PI3K/AKT/mTOR通路调控他克莫司诱导儿童肾毒性的机制研究，2022.01-2024.12，主持

2. 徐州市推动科技创新专项资金重点研发计划（社会发展），KC21257，基于临床药学关键前沿技术PBPK/PPK/PD/PG的儿童患者免疫抑制剂精准治疗，2021.09-2023.08，主持

3. 徐州医科大学优秀人才科研启动基金，D2021012，模型引导的免疫抑制剂精准治疗，2021.05-2024.04，主持

4. 徐州医科大学“融合创新”项目，XYRHCX2021011，基于模型引导的药物研发新模式：推荐防治GVHD的新药在临床试验中给药方案，2021.07-2024.07，主持

5. 江苏省教育科学规划课题，C/2022/01/36，基于MIPD的创新型临床药学专业人才培养模式探索与实践，2023.01-2024.12，主持

6. 江苏省高校教育信息化研究课题，2023JSETKT136，产教融合“四方合作”探索具有MIDD/MIPD人工智能信息化背景的一流临床药学本科生育人机制，2023.09-2025.08，主持

指导学生课题与获奖

1. 国家级大学生创新创业训练项目，202110313024，基于群体药动学与蒙特卡罗模拟：他克莫司在儿童肺移植患者的个体化给药，指导

2. 国家级大学生创新创业训练项目，202210313053，基于临床药学MBMA技术预测达格列净对2型糖尿病患者体重的影响及最佳治疗方案推荐，指导

3. 基础医学国家级实验教学示范中心学生科创项目，基于MIPD/AI探究精神分裂症患者阿立哌唑的药物相互作用及其个体化精准给药，共同指导

4. 第十五届全国大学生药苑论坛，基于MIPD分析精神分裂症患者阿立哌唑的药物相互作用及其个体化药学服务，创新成果一等奖、优秀论文奖，共同指导

5. 第二届长三角高校本科生临床药学技能邀请赛，基于MIPD分析精神分裂症患者阿立哌唑的药物相互作用及其个体化药学服务，二等奖，共同指导

近五年代表性论文（第一作者/主要通讯）

1.    Chen X, Hu K, Zhang Y, He SM, Wang DD. Targeting CXCR2 ameliorated tacrolimus-induced nephrotoxicity by alleviating overactivation of PI3K/AKT/mTOR pathway and calcium overload. Biomed Pharmacother. 2024 Oct 7;180:117526.

2.    Chen X, Hu K, Shi HZ, Chen L, Zhang YJ, He SM, Zhang C, Wang DD. Initial dosage optimization of olanzapine in patients with bipolar disorder based on model-informed precision dosing: a study from the real world. Front Pharmacol. 2024 Aug 21;15:1444169.

3.    Hu K, Pan JJ, Qu WQ, He SM, Yang Y, Shi HZ, Zhang YJ, Chen X, Wang DD. Weight, CYP3A5 Genotype, and Voriconazole Co-administration Influence Tacrolimus Initial Dosage in Pediatric Lung Transplantation Recipients with Low Hematocrit based on a Simulation Model. Curr Pharm Des. 2024;30(34):2736-2748.

4.    Shen W, Hu K, Shi HZ, Jiang L, Zhang YJ, He SM, Zhang C, Chen X, Wang DD. Effects of Sex Differences and Combined Use of Clozapine on Initial Dosage Optimization of Valproic Acid in Patients with Bipolar Disorder. Curr Pharm Des. 2024;30(29):2290-2302.

5.    Zhang C, Jiang L, Hu K, Zhang YJ, Han J, Chen J, Bulubu, Dong B, Shi HZ, He SM, Yu TT, Chen X, Wang DD. Drug-drug interaction and initial dosage optimization of aripiprazole in patients with schizophrenia based on population pharmacokinetics. Front Psychiatry. 2024 Jun 18;15:1377268.

6.    Rui M, Jiang L, Pan JJ, Huang XT, Cui JF, Zhang SJ, He SM, Han HH, Chen X, Wang DD. Effects of tacrolimus on proteinuria in Chinese and Indian patients with idiopathic membranous nephropathy: the results of machine learning study. Int Urol Nephrol. 2024 Sep;56(9):3047-3055.

7.    Zhang C, Jiang L, Hu K, Chen L, Zhang YJ, Shi HZ, He SM, Chen X, Wang DD. Effects of Aripiprazole on Olanzapine Population Pharmacokinetics and Initial Dosage Optimization in Schizophrenia Patients. Neuropsychiatr Dis Treat. 2024 Mar 4;20:479-490.

8.    Hu K, He SM, Zhang C, Zhang YJ, Gu Q, Shi HZ, Wang DD. Optimizing the initial tacrolimus dosage in Chinese children with lung transplantation within normal hematocrit levels. Front Pediatr. 2024 Jan 31;12:1090455.

9.    Chen X, Hu K, Shi HZ, Zhang YJ, Chen L, He SM, Wang DD. Syk/BLNK/NF-κB signaling promotes pancreatic injury induced by tacrolimus and potential protective effect from rapamycin. Biomed Pharmacother. 2024 Jan 5;171:116125.

10. Chen X, Xu C, Hu K, Yang Y, Zhang YJ, Shi HZ, Gu Q, He SM, Zhang C, Wang DD. Quantitative effects of sodium-glucose cotransporter-2 inhibitors on liver functions in patients with nonalcoholic fatty liver disease. Expert Rev Clin Pharmacol. 2023 Jul-Dec;16(10):991-998.

11. Hu K, Fu M, Huang X, He S, Jiao Z, Wang D. Editorial: Model-informed drug development and precision dosing in clinical pharmacology practice. Front Pharmacol. 2023 Jun 30;14:1224980.

12. Wang DD, Zhang C, Hu K, He SM, Zhu P, Chen X. Therapeutic effect and rebound evaluation of dapagliflozin on glycated hemoglobin (HbA1c) in type 1 diabetes mellitus patients. Front Pharmacol. 2023 Jan 4;13:972878.

13. Wang DD, Zhang C, Zhu P, He SM, Chen X. Quantitative effects of sodium-glucose cotransporter-2 inhibitors dapagliflozin and empagliflozin on quality of life in heart failure patients. Front Pharmacol. 2022 Nov 28;13:910858.

14. Wang DD, Li YF, Zhang C, He SM, Chen X. Predicting the effect of sirolimus on disease activity in patients with systemic lupus erythematosus using machine learning. J Clin Pharm Ther. 2022 Nov;47(11):1845-1850.

15. Wang DD, Li YF, Mao YZ, He SM, Zhu P, Wei QL. A machine-learning approach for predicting the effect of carnitine supplementation on body weight in patients with polycystic ovary syndrome. Front Nutr. 2022 Aug 10;9:851275.

16. Wang DD, Zhang C, Yang Y, He SM, Zhu P, Chen X. Effects of Sodium-Glucose Cotransporter-2 Inhibitors on Urine Albumin to Creatinine Ratio in Type 2 Diabetes Mellitus Patients and Medication Care. J Diabetes Res. 2022 Jul 20;2022:5854200.

17. Wang DD, Mei YQ, Yang L, Ding KW, Xue JJ, Wang X, He SM, Wei QL. Optimization of initial dose regimen of tacrolimus in paediatric lung transplant recipients based on Monte Carlo simulation. J Clin Pharm Ther. 2022 Oct;47(10):1659-1666.

18. Wang DD, He SM, Yang Y, Mao YZ, Yin D, Zheng ZQ, Chen X. Effects of cimetidine on ciclosporin population pharmacokinetics and initial dose optimization in aplastic anemia patients. Eur J Pharm Sci. 2022 Jul 1;174:106183.

19. Wang DD, Mao YZ, Yang Y, Wang TY, Zhu P, He SM, Chen X. Effects of Sodium-Glucose Cotransporter-2 Inhibitors on Weight in Type 2 Diabetes Mellitus and Therapeutic Regimen Recommendation. J Diabetes Res. 2022 Mar 18;2022:4491900.

20. Wang DD, Wang TY, Yang Y, He SM, Wang YM. The Effects of L-Carnitine, Acetyl-L-Carnitine, and Propionyl-L-Carnitine on Body Mass in Type 2 Diabetes Mellitus Patients. Front Nutr. 2021 Nov 8;8:748075.

21. Wang DD, He SM, Han Y, Wang TY, Wang YM. Quantifying the relationship between dapagliflozin and loss of weight in type 1 diabetes mellitus patients. J Clin Pharm Ther. 2022 Feb;47(2):237-242.

22. Wang DD, Mao YZ, He SM, Chen X. Analysis of Time Course and Dose Effect From Metformin on Body Mass Index in Children and Adolescents. Front Pharmacol. 2021 Apr 26;12:611480.

23. Wang DD, Mao YZ, He SM, Yang Y, Chen X. Quantitative efficacy of L-carnitine supplementation on glycemic control in type 2 diabetes mellitus patients. Expert Rev Clin Pharmacol. 2021 Jul;14(7):919-926.

24. Wang DD, Chen X, Xu H, Li ZP. Initial Dosage Recommendation for Sirolimus in Children With Tuberous Sclerosis Complex. Front Pharmacol. 2020 Jun 11;11:890.

25. Wang D, Chen X, Fu M, Xu H, Li Z. Tacrolimus increases the expression level of the chemokine receptor CXCR2 to promote renal fibrosis progression. Int J Mol Med. 2019 Dec;44(6):2181-2188.

26. 王栋栋, 陈肖, 何素梅, 冯英成, 张村, 赵子明. 产教融合“四方合作”在MIDD/MIPD背景下临床药学本科生创新培养模式的探索与实践. 卫生职业教育, 2024, 42(12):4-8.

27. 王栋栋. 基于MIPD的创新型临床药学专业人才培养模式探索.卫生职业教育, 2023, 41(22):1-4.

28. 王栋栋. 群体药动学在临床药学专业的教学策略设计.基础医学教育, 2022, 24(09):672-675.

29. 王栋栋. 临床药学本科专业开展MIDD案例教学的建议与思考.高校医学教学研究(电子版), 2022, 12(04):15-19.

30. 王栋栋. 群体药动学在临床药学专业本科教学的思考与建议.基础医学教育, 2021, 23(12):839-841.